dataset
posted on 2023-04-03, 19:44 authored by Lauren G. Aoude, Bernadette Z.Y. Wong, Vanessa F. Bonazzi, Sandra Brosda, Shaun B. Walters, Lambros T. Koufariotis, Marjan M. Naeini, John V. Pearson, Harald Oey, Kalpana Patel, Julia J. Bradford, Conor J. Bloxham, Victoria Atkinson, Phillip Law, Geoffrey Strutton, Gerard Bayley, Samuel Yang, B. Mark Smithers, Nicola Waddell, Kenneth Miles, Andrew P. Barbour Table S1. Patient Characteristics. AJCC: American Joint Committee on Cancer Table S2. Clinical information including histology, stage and survival. Table S3. Univariate analysis of clinico-pathological and CT features. Log-rank (Mantel-Cox) test to determine optimal cut-offs for low/high groups. Table S4. RNAseq immune genes for multiplex analysis.
Funding
National Health and Medical Research Council of Australia (NHMRC)
NHMRC
Collaborative Cancer Research Scheme, Cure Cancer Australia
History
ARTICLE ABSTRACT
Treatment for metastatic melanoma includes targeted and/or immunotherapy. Although many patients respond, only a subset has complete response. As late-stage patients often have multiple tumors in difficult access sites, non-invasive techniques are necessary for the development of predictive/prognostic biomarkers. PET/CT scans from 52 patients with stage III/IV melanoma were assessed and CT image parameters were evaluated as prognostic biomarkers. Analysis indicated patients with high standard deviation or high mean of positive pixels (MPP) had worse progression-free survival (P = 0.00047 and P = 0.0014, respectively) and worse overall survival (P = 0.0223 and P = 0.0465, respectively). Whole-exome sequencing showed high MPP was associated with BRAF mutation status (P = 0.0389). RNA-sequencing indicated patients with immune “cold” signatures had worse survival, which was associated with CT biomarker, MPP4 (P = 0.0284). Multiplex immunofluorescence confirmed a correlation between CD8 expression and image biomarkers (P = 0.0028).
CT parameters have the potential to be cost-effective biomarkers of survival in melanoma, and reflect the tumor immune-microenvironment.
